ASCO 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma - Episode 13

Select Ongoing Trials for nccRCC and Impact on the Treatment Landscape

, , ,
EP. 1: Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC
EP. 2: Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER
EP. 3: Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC
EP. 4: Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials
EP. 5: Exciting Data and Trials in Progress from ASCO 2024
EP. 6: Ongoing RCC Clinical Trials that may Impact Practice
EP. 7: Dr Xu Provides Clinical Perspective on the CONTACT-03 Trial Outcomes
EP. 8: Dr Voss Application of Updated KEYNOTE-564 Data
EP. 9: Guiding Sequencing & Finding a Contemporary Regimen/ Approach to Treatment Post-Checkpoint Inhibition
EP. 10: World Health Organization (WHO) Classification Updates for Papillary RCC
EP. 11: Additional Forward-Looking Data and Studies Beyond Frontline Therapy in RCC
EP. 12: The Role of Chemotherapy in nccRCC Treatment
Now Viewing
EP. 13: Select Ongoing Trials for nccRCC and Impact on the Treatment Landscape
EP. 14: Final Thoughts/Looking Forward
  1. Please review ongoing trials for patients with nccRCC and discuss the potential impact of these studies on the treatment landscape.
  2. Phase 2 KEYNOTE-B61 trial, comparing len + pembro in 1L nccRCC 
  3. Please provide a brief background surrounding KEYNOTE-B61
  4. Please discuss extended follow-up presented at ASCO GU 2024
  5. Phase 2 trial assessing nivo + cabo (